Home › Research › Brain scans and imaging
Combining CSF MTBR-tau243 and plasma pTau217 ratio enhances the prediction of continuous regional tau PET burden in early Alzheimer's disease
Viswanath Devanarayan, Kanta Horie, Kristin Wildsmith, Thomas Doherty, Erica Andreozzi, Arnaud Charil, Pallavi Sachdev, Lynn D Kramer et al.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025-11
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Plasma pTau217R matched CSF eMTBR-tau243 and outperformed MTBR-tau243. Combining pTau217R with either CSF marker improved prediction (R2 to 0.74; AUROC to 0.94) and could reduce PET use by 58%-80% for prescreening at 10% false negatives. Plasma pTau217R plus CSF eMTBR-tau243 predict regional tau burden and may reduce reliance on tau PET in early AD trials. GOV IDENTIFIERS: NCT03887455 (ClarityAD) HIGHLIGHTS: Combining plasma pTau217R and CSF eMTBR‑tau243 improves tau PET prediction. The model predicts regional tau PET SUVRs with high accuracy across key regions. Single-marker models show pTau217R and eMTBR-tau243 outperform MTBR-tau243. PET‑sparing triage reduces scan burden by up to 80% at 10% false negatives. Stochastic gradient boosting enables region-specific tau PET prediction in one unified model.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Devanarayan, V., Horie, K., Wildsmith, K., Doherty, T., Andreozzi, E., Charil, A., et al. (2025). Combining CSF MTBR-tau243 and plasma pTau217 ratio enhances the prediction of continuous regional tau PET burden in early Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.70881
Vancouver
Devanarayan V, Horie K, Wildsmith K, Doherty T, Andreozzi E, Charil A, et al. Combining CSF MTBR-tau243 and plasma pTau217 ratio enhances the prediction of continuous regional tau PET burden in early Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. doi:10.1002/alz.70881. PMID: 41170658.
BibTeX
@article{devanarayan2025-41170658,
author = {Devanarayan, Viswanath and Horie, Kanta and Wildsmith, Kristin and Doherty, Thomas and Andreozzi, Erica and Charil, Arnaud and Sachdev, Pallavi and Kramer, Lynn D and others},
title = {{Combining CSF MTBR-tau243 and plasma pTau217 ratio enhances the prediction of continuous regional tau PET burden in early Alzheimer's disease}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2025},
doi = {10.1002/alz.70881},
pmid = {41170658},
url = {https://doi.org/10.1002/alz.70881}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Plasma pTau217R matched CSF eMTBR-tau243 and outperformed MTBR-tau243.
- Combining pTau217R with either CSF marker improved prediction (R2 to 0.74; AUROC to 0.94) and could reduce PET use by 58%-80% for prescreening at 10% false negatives.
- Plasma pTau217R plus CSF eMTBR-tau243 predict regional tau burden and may reduce reliance on tau PET in early AD trials.
- GOV IDENTIFIERS: NCT03887455 (ClarityAD) HIGHLIGHTS: Combining plasma pTau217R and CSF eMTBR‑tau243 improves tau PET prediction.
- The model predicts regional tau PET SUVRs with high accuracy across key regions.
New to this subject? Start with our plain-English guide: Brain scans & tests →
Study details
- Participants242
- Evidence strengthLow
How this study scored 75/100
Published in a leading specialty journal, and it is a large phase 3 trial. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and free to read, so those were left out: it earned 44 of the 59 points we could judge it on, which is 75 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A large phase 3 trial (from PubMed type “Clinical Trial, Phase III”) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 242 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41170658) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 44 / 59 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 44 of the 59 points we could judge it on is 75 out of 100. |
| Total | 75 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Brain scans and imaging from nearby years
Also tagged “18f”
318 studies in the library carry the topic tag “18f”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 318 tagged studies.